Linearity [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-01-24 16:06 (1262 d 09:29 ago) – Posting: # 22752
Views: 4,275

Hi Ohlbe,

❝ Does your drug show linear PK ? If not: does it show more-than-proportional increase (then the highest strength would be more sensitive to show differences in BA) or less-than-proportional increase (lowest strength would be more sensitive, giving you good arguments) ?


Yes its linear PK. I read the FDA guidance about Guidance, for NDA it seeems "possible" as long as one can provide safety and efficacy data.

John

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,691 registered users;
23 visitors (0 registered, 23 guests [including 9 identified bots]).
Forum time: 02:36 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5